Wahid Hanna, MD
Hematology · Knoxville, TNNPI 1093761124
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Astrazeneca AB at 34.0% of the total. Reporting peaked in 2019 at $7,549 and has fallen 81.8% since, to $1,374 in 2025.
Across 479 payments — averaging $37.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca AB$6K
- Merck$2K
- Novartis$912
- AstraZeneca$719
- EMD Serono, Inc.$564
- Incyte Corporation$553
- plus $7K from 54 others
Across 211 payments — averaging $6411.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$577K
- Astrazeneca UK Limited$302K
- E.r. Squibb & Sons, L.L.C.$118K
- Bristol Myers Squibb$82K
- Dr.reddy's Laboratories,inc.$77K
- Eisai Inc.$46K
- plus $150K from 8 others
What the payments were for
- Consulting fees$5003%
- Travel & lodging$7,58542%
- Food & beverage$9,54752%
- Education$5683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,200 in reported general payments places this provider in the 70th percentile of 23 hematology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 162 | $2,736,458 |
| PomalystPomalidomide | 86 | $1,607,886 |
| PromactaEltrombopag Olamine | 84 | $1,419,439 |
| TasignaNilotinib Hcl | 96 | $1,269,751 |
| ImbruvicaIbrutinib | 106 | $1,213,651 |
| CalquenceAcalabrutinib Maleate | 113 | $1,110,372 |
| BrukinsaZanubrutinib | 110 | $1,084,311 |
| RevlimidLenalidomide | 60 | $788,009 |
| KisqaliRibociclib Succinate | 56 | $641,449 |
| XtandiEnzalutamide | 53 | $582,203 |
| OjjaaraMomelotinib Dihydrochloride | 21 | $561,004 |
| DopteletAvatrombopag Maleate | 43 | $450,721 |
| Lenalidomide | 42 | $433,336 |
| EliquisApixaban | 424 | $352,522 |
| XareltoRivaroxaban | 321 | $295,347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisPromacta, Tasigna, Kisqali, Mekinist, Tafinlar | $912 | $3,933,398288 claims |
| Incyte CorporationJakafi | $553 | $2,736,458162 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $546 | $1,727,479113 claims |
| AstraZenecaCalquence, Tagrisso, Lynparza | $719 | $1,573,740141 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $46 | $1,213,651106 claims |
| Beigene USA, Inc.Brukinsa | $82 | $1,084,311110 claims |
| Bristol Myers SquibbRevlimid | $486 | $788,00960 claims |
| Astellas Pharma US IncXtandi | $130 | $582,20353 claims |
| GSKOjjaara | $97 | $561,00421 claims |
| Lilly USA, LLCJaypirca, Retevmo | $79 | $460,07625 claims |
| PfizerEliquis | $349 | $352,522424 claims |
| Johnson & JohnsonXarelto | $231 | $295,347321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 23 hematology providers in Tennessee.
Other hematology in Knoxville
- Stephen StricklandNashville$120K
- Michael SavonaNashville$100K
- Ashwin KishtagariNashville$88K
- Navneet MajhailNashville$58K
- Douglas KingmaFranklin$35K
- Adetola KassimNashville$26K
- Michael ByrneNashville$18K
- Robert CornellNashville$17K
- Anne NeffNashville$5K
- Silvia BuntingNashville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.